Phase I-II Study of MEK 162 for Children with Low-Grade Gliomas and Other Ras/Raf/ERK Pathway Activated Tumors
Brief description of study
If you or your child has been diagnosed with low-grade gliomas, you or your child may qualify to participate in a study evaluating the safety and effectiveness of the investigational drug, MEK162, a dual specific kinase inhibitor, which blocks a critical regulator in a key pathway that helps control cells' ability to grow and survive. The main goal of this phase I-II study is to find out what effects, good and/or bad, MEK162 has on people with low-grade gliomas. In addition, we would like to explore the pharmacodynamic effect of the investigational drug, MEK162 on biomarkers (proteins) of a specific signaling pathway. This study will be conducted in two phases: Phase I will consist of defining the toxicity profile of the investigational drug. Phase II will help determine how the investigational drug reacts to your cancer.
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.